Remimazolam for Colonoscopy in IBD Patients

Remimazolam for Colonoscopy in IBD Patients

The goal of this clinical trial is to compare two sedation regimens-remimazolam and midazolam-for colonoscopy in adult patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.

The main questions it aims to answer are:

• Does remimazolam provide patient satisfaction that is non-inferior to midazolam during colonoscopy?
• Does remimazolam allow faster recovery and discharge readiness compared to midazolam?

Researchers will compare sedation with remimazolam plus fentanyl to sedation with midazolam plus fentanyl to see if remimazolam improves patient experience and procedural efficiency.

Participants will:

• Receive either remimazolam or midazolam, each combined with fentanyl, during their scheduled colonoscopy
• Complete a short questionnaire to rate their satisfaction after the procedure
• Be assessed for recovery using a standardized discharge score at 10 and 20 minutes after the procedure

• Inclusion Criteria

  • Age ≥18 years
  • Diagnosis of IBD (CD or UC) for ≥6 months
  • Scheduled colonoscopy for clinical or surveillance purposes
  • Ability to provide informed consent

• Exclusion Criteria

  • ASA class IV
  • Allergy to benzodiazepines, opioids, flumazenil, or naloxone
  • Severe COPD
  • Obstructive sleep apnea
  • BMI >35
  • Pregnancy or lactation
  • Prior multiple ileocolonic resections or subtotal colectomy
  • Inability to complete questionnaires